Calamos Advisors LLC Sells 6,333 Shares of Bristol-Myers Squibb (NYSE:BMY)

Calamos Advisors LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 0.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 673,769 shares of the biopharmaceutical company’s stock after selling 6,333 shares during the quarter. Calamos Advisors LLC’s holdings in Bristol-Myers Squibb were worth $34,571,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OFI Invest Asset Management acquired a new position in Bristol-Myers Squibb during the third quarter valued at approximately $25,000. True Wealth Design LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at $26,000. Milestone Investment Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth $27,000. Coppell Advisory Solutions LLC bought a new stake in shares of Bristol-Myers Squibb during the 2nd quarter worth $28,000. Finally, Blue Bell Private Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 200 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the subject of several research analyst reports. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Finally, Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Stock Up 1.0 %

BMY stock traded up $0.46 during trading on Thursday, reaching $48.30. The stock had a trading volume of 10,913,290 shares, compared to its average volume of 15,781,784. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The company’s 50 day moving average is $51.26 and its two-hundred day moving average is $51.59. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $97.89 billion, a price-to-earnings ratio of 12.46, a P/E/G ratio of 1.49 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same period last year, the business posted $1.82 earnings per share. Bristol-Myers Squibb’s revenue was up .6% on a year-over-year basis. Equities research analysts forecast that Bristol-Myers Squibb will post 6.47 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.97%. Bristol-Myers Squibb’s payout ratio is currently 62.18%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.